查詢結果分析
相關文獻
- 血漿中骨髓過氧化酶的濃度可做為評估與預防急性心肌梗塞之指標
- 動脈硬化及其併發症--發炎反應扮演之角色
- 急性心肌梗塞住院病人的不確定感與因應行為之探討
- Myocardial Contrast Echocardiography and Dobutamine Echocardiography in Predicting Viable Myocardium
- 連續一週的密集等速離心訓練對肌肉損傷和發炎反應評估指標的影響
- 急性心肌梗塞治療
- 急性心肌梗塞的輔助治療
- Sex Difference in the Mortality Trends of Acute Myocardial Infarction in Taiwan, 1974 to 1993
- Cardiac Rupture in Patients with Acute Myocardial Infarction: Report of Three Cases and Review
- Unilateral Renal Hemorrhage Following Thrombolytic Therapy for Acute Myocardial Infarction--A Case Report
頁籤選單縮合
| 題 名 | 血漿中骨髓過氧化酶的濃度可做為評估與預防急性心肌梗塞之指標=Plasma Myeloperoxidase as a Maker for the Evaluation and Prevention of Acute Myocardial Infarction |
|---|---|
| 作 者 | 古伯文; 鄭美玲; 甯孝眞; 吳竹蘭; 孫建峰; 陳進明; 趙崇義; | 書刊名 | Journal of Biomedical & Laboratory Sciences |
| 卷 期 | 19:3 2007.09[民96.09] |
| 頁 次 | 頁76-83 |
| 分類號 | 415.319 |
| 關鍵詞 | 骨髓過氧化酶; 急性心肌梗塞; 發炎反應; Myeloperoxidase; Acute myocardial infarction; Inflammation; |
| 語 文 | 中文(Chinese) |
| DOI | 10.30046/JBLS.200709.0002 |
| 中文摘要 | 發炎反應在急性心肌梗塞(Acute Myocardial Infarction, AMI)發生的過程中,扮演著非常重要的角色,它包含了白血球的聚集與活化。白血球富含一種稱爲骨髓過氧化酶(myeloperoxidase),簡稱MPO的酵素,當發炎反應發生時,白血球活化會將MPO釋放出來。在本次研究中,爲了評估血漿中MPO含量的偵測是否有助於AMI的評估與預防,我們收集了四十名AMI病患爲研究對象,再收集四十名健康檢查的病人爲控制組,以BIOXYTECH(上标 ®)MPO-EIA(上標 TM)試劑套組定量血漿中MPO的含量,同時以自動化機台進行白血球計數,以及整理與分析相關的臨床資料。此外,我們還針對AMI病患的檢體以自動化機台進行Troponin Ⅰ及CK-MB的定量分析,以比較三者的結果。研究結果顯示,AMI病患組相較於控制組,其MPO的含量有大於十倍的上升(149.7±103.7比14.0±7.0ng/mL)。雖然病患組的Troponin Ⅰ及CK-MB的平均值均超過參考值,但是就個體而言,其中有4位病患的數值,仍屬正常範圍內,但其MPO含量已遠高於控制組的分布範圍。而分析潛在疾病及心血管病史發生的比例,我們發現病患組中出現高血壓及罹患糖尿病的人數高於控制組,但是出現高血脂的人數反而是控制組高於病患組,且皆具有統計上的差異。MPO的含量與白血球數目之間具有明顯的相關性。而血脂異常的AMI病患,其MPO含量有一致偏高的現象,且和無血脂異常的AMI病患比較,其MPO含量在統計上有相關性。綜合以上結果,我們初步確立了偵測血漿中MPO的含量將有助於AMI的評估與預防,未來將做更完整的評估,以發揮其臨床的運用性。 |
| 英文摘要 | Inflammation is one of the major risk factors of acute myocardial infarction (AMI), and is associated with recruitment and activation of leukocytes. Myeloperoxidase (MPO), a highly abundant leukocyte enzyme, is secreted by leukocytes during inflammation. To evaluate the role of applicability of plasma MPO as a marker for the evaluation and prevention of AMI, we collected and studied clinical specimens from 40 AMI patients and 40 healthy control subjects. Plasma levels of MPO were determined by using a commercial kit (BIOXYTECH(superscript ®) MPO-EIA(superscript TM)). Leukocyte counts were determined by using an automatic cell counter. Medical records were reviewed and analyzed statistically. Levels of Troponin Ⅰ and CK-MB (both determined by automatic analyzers) from the AMI patients were determined. Our data showed that the average levels of MPO from the AMI patients were ten-fold higher than those of control group (149.7±103.7 ng/mL vs. 14.0±7.0 ng/mL). The average levels of Troponin Ⅰ and CK-MB in the patient group were higher than the normal values. Four AMI patients had normal levels of Troponin Ⅰ and CK-MB. However, their plasma MPO levels were all far above normal ranges, implying that MPO may be more useful as a marker. Analysis of the correlation between underlying diseases and cardiovascular diseases revealed that AMI patients had significantly higher proportions of hypertension and diabetes mellitus as composed to control subjects. In contrast, the percentage hyperlipidemia was significantly lower in AMI group. Significant correlation was also found between plasma levels of MPO and the respective leukocyte counts. Among the AMI patients, plasma MPO levels were significantly higher in patients with hyperlipidemia. In conclusion, the present study demonstrates the prognostic value of plasma MPO in the onset of AMI. |
本系統中英文摘要資訊取自各篇刊載內容。